Can She Stay at 10mg Zepbound After Achieving Goal Weight?
No, she should continue tirzepatide therapy at her current 10mg dose (or maximum tolerated dose) rather than discontinuing or reducing it, as stopping or lowering the dose leads to substantial weight regain.
The Evidence for Continued Treatment
The most definitive evidence comes from the SURMOUNT-4 trial, which directly addresses this question. When patients who achieved weight loss on tirzepatide were randomized to either continue treatment or switch to placebo, those who discontinued experienced a mean weight regain of 14.0% by week 88, while those who continued lost an additional 5.5% 1. Overall, 89.5% of patients continuing tirzepatide maintained at least 80% of their weight loss compared to only 16.6% who switched to placebo 1.
The more recent SURMOUNT-MAINTAIN trial (2026) reinforces this finding with even stronger data. Patients who continued tirzepatide at their maximum tolerated dose (10mg or 15mg) maintained a 21.9% weight reduction from baseline at 112 weeks, compared to only 9.9% in those switched to placebo—a 12% absolute difference 2. Critically, this trial also tested dose reduction: patients lowered to 5mg experienced intermediate outcomes with 16.6% weight reduction, but still required rescue therapy in 25% of cases versus only 8% who stayed at maximum tolerated dose 2.
Why Staying at 10mg Matters for Long-Term Health
Obesity is a chronic disease requiring ongoing treatment. The 2025 AACE guidelines explicitly state that tirzepatide has demonstrated weight reduction maintenance when treatment continues for 88 weeks 3. The biological reality is that discontinuation or dose reduction triggers weight regain through metabolic adaptation and return of appetite dysregulation.
Real-world data from 2026 supports trial findings: among patients persistent on tirzepatide for ≥12 months, median weight loss was 14.4%, and those who remained on therapy showed sustained cardiometabolic benefits 4. In a large US claims analysis, 68% of patients remained persistent at 6 months, achieving 10.5% mean weight reduction with numerical improvements in cardiometabolic risk factors 5.
The Dose Reduction Alternative (Not Recommended)
While the SURMOUNT-MAINTAIN trial showed that reducing to 5mg is superior to complete discontinuation, this is a compromise option, not an optimal strategy 2. Patients on 5mg experienced:
- More weight regain than those at maximum tolerated dose (6.6% difference)
- Three times higher need for rescue therapy (25% vs 8%)
- Less maintenance of cardiometabolic benefits
If your patient tolerates 10mg well, there is no evidence-based reason to reduce the dose after achieving goal weight.
Practical Management Algorithm
Continue 10mg weekly indefinitely as long as:
- No intolerable side effects
- Patient can access/afford medication
- No contraindications develop
Monitor for:
- Weight stability (monthly initially, then quarterly)
- Cardiometabolic parameters (lipids, blood pressure, glucose)
- Gastrointestinal tolerance
- Signs of gallbladder disease (given increased risk with weight loss) 3
Only consider dose reduction to 5mg if:
- Cost/access becomes prohibitive
- Persistent intolerable side effects at 10mg
- Patient strongly prefers lower dose
- But counsel that weight regain risk increases significantly
Never abruptly discontinue unless medically necessary, as this guarantees substantial weight regain 2, 1
Common Pitfalls to Avoid
The "goal weight achieved, stop medication" mindset is the most dangerous error. This treats obesity like an acute infection rather than the chronic disease it is. The 2025 BMJ guidelines emphasize that tirzepatide's benefits extend beyond weight loss to include prevention of diabetes progression, improvement in obstructive sleep apnea, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatohepatitis 6, 3.
If the patient must pause treatment (e.g., for surgery, pregnancy planning), counsel that restarting requires titration from 2.5mg again to allow physiologic adaptation 3. Attempting to restart at 10mg after a gap risks severe gastrointestinal side effects.
The Bottom Line
Your patient achieved her goal weight because of the 10mg dose. Maintaining that weight requires maintaining that dose. The evidence unequivocally shows that discontinuation or dose reduction leads to weight regain, loss of cardiometabolic benefits, and potential need for rescue therapy. Continue 10mg weekly as chronic disease management, not as a temporary intervention.